These studies reveal an unexpected finding — a nonredundant role for the autocrine mPGES-1/PGE2/EP4 signaling axis in pancreatic cancer cells, further nominating mPGES-1 inhibition and EP4 blockade as immune-sensitizing therapy in cancer. Here, PTGER4 is linked to familial pancreatic carcinoma.